tbuckley/cabot-search huggingface dataset:
Applied Anatomy. The Construction of the Human Body Considered in Relation to Its Functions, Diseases and Injuries.
Authors: Gwilym George Davis
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biological Clock Ticks for Men, Too
Authors: Paul D Thacker
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
Authors: Weiping Zou, Véronique Machelon, Aurore Coulomb-L'Hermin, Jozef Borvak, Françoise Nome, Tatyana Isaeva, Shuang Wei, Roman Krzysiek, Ingrid Durand-Gasselin, Alan Gordon, Terri Pustilnik, David T. Curiel, Pierre Galanaud, Frédérique Capron, Dominique Emilie, Tyler J. Curiel
Journal: Nature Medicine (2001)
Leukaemia cutis and erythroleukaemia
Authors: None Janier, None Raynaud, None Blanche, None Daniel, None Herreman
Journal: British Journal of Dermatology (1999)

Journal Article Leukaemia cutis and erythroleukaemia Get access M. Janier, M. Janier Fondation Hôpital St Joseph, 185 rue Raymond Losserand, 75014 Paris, France Search for other works by this author on: Oxford Academic Google Scholar E. Raynaud, E. Raynaud Fondation Hôpital St Joseph, 185 rue Raymond Losserand, 75014 Paris, France Search for other works by this author on: Oxford Academic Google Scholar P. Blanche, P. Blanche Fondation Hôpital St Joseph, 185 rue Raymond Losserand, 75014 Paris, France Search for other works by this author on: Oxford Academic Google Scholar F. Daniel, F. Daniel Fondation Hôpital St Joseph, 185 rue Raymond Losserand, 75014 Paris, France Search for other works by this author on: Oxford Academic Google Scholar G. Herreman G. Herreman Fondation Hôpital St Joseph, 185 rue Raymond Losserand, 75014 Paris, France Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 141, Issue 2, 1 August 1999, Pages 372–373, https://doi.org/10.1046/j.1365-2133.1999.03010.x Published: 01 August 1999
Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy
Authors: Justin K. Lee, Melissa Assel, Alan E. Thong, Daniel D. Sjoberg, John P. Mulhall, Jaspreet Sandhu, Andrew J. Vickers, Behfar Ehdaie
Journal: European Urology (2015)
494. Topical Delivery of mRNA to the Murine Lung and Nasal Epithelium
Authors: Hazel Painter, Stephanie G. Sumner-Jones, Seng H. Cheng, Steve C. Hyde, Deborah R. Gill
Journal: Molecular Therapy (2004)

One of the significant barriers to non-viral gene transfer in vivo is penetration of the nuclear membrane. mRNA, which is translated in the cytoplasm and therefore does not need to negotiate nuclear transport, is being evaluated for gene transfer in vivo. A plasmid expressing firefly luciferase (pSP64-lux-Poly(A)) was constructed and linearised to serve as a template for in vitro transcription (yield was 2.0mg RNA per 1ml reaction). HEK293T cells were transfected with 2g mRNA (encoding luciferase) complexed with 4g cationic lipid (DOTAP) and luciferase expression was observed 9 hours after transfection, confirming the integrity of the luciferase mRNA. For in vivo delivery, luciferase-expressing mRNA was complexed with Genzyme lipid GL67 (80g RNA/60nmol GL67) and dosed to the lungs of female BALB/c mice (6–8 weeks) via intranasal instillation. Lungs were harvested at 3, 6, 12, and 24 hours after delivery (n = 5–6 per group). At 3 hours, mean luciferase expression was five-fold greater than that of naive animals (mRNA: 0.236 0.089 RLU/mg protein, naive: 0.047 0.019 RLU/mg protein) (ANOVA with Fisher's PLSD, p = 0.0001). mRNA dependent reporter gene expression decreased with time and was lower than expression from luciferase expressing plasmid DNA. In vivo delivery was also demonstrated following perfusion to the mouse nose. Naked mRNA (150g), mRNA/DOTAP (100g) or mRNA/DOTAP-Chol (25g) was delivered to female BALB/c mice (n=7). The reagents were delivered in a total volume of 100l and perfused over 15 minutes. Nasal tissue was harvested and measured for luciferase activity after 4 hours. Naked mRNA generated a mean luciferase activity approximately 500 fold over values of mRNA/DOTAP, mRNA/DOTAP-Chol and naive groups (ANOVA, p = 0.0001). The lack of expression seen with the mRNA/lipid complexes in the nasal epithelium could be due to the route of entry for these complexes via endocytosis and/or the release of the mRNA into the cytoplasm may take longer than 4 hours. This study demonstrates that mRNA can be used to deliver and express transgenes in the mouse lung and nose. Gene replacement therapy is being considered as a potential treatment for Cystic Fibrosis, where absence of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein from the respiratory epithelium results in fatal lung disease. As only a small amount of CFTR expression may be needed per cell to achieve normal levels (Trapnell et al, 1991, PNAS 88:6565–6569), the use of mRNA might offer advantages over other gene transfer agents, depending on the number of cells transfected in vivo. Time course and dose response studies of mRNA expression in the mouse nose are underway. Further studies using GFP mRNA will investigate the number and type of cells transfected.
Prenatal <i>p,p´</i> -DDE Exposure and Neurodevelopment among Children 3.5–5 Years of Age
Authors: Luisa Torres-Sánchez, Lourdes Schnaas, Stephen J. Rothenberg, Mariano E. Cebrián, Erika Osorio-Valencia, María del Carmen Hernández, Rosa María García-Hernández, Lizbeth López-Carrillo
Journal: Environmental Health Perspectives (2012)

The results of previous studies suggest that prenatal exposure to bis[p-chlorophenyl]-1,1,1-trichloroethane (DDT) and to its main metabolite, 2,2-bis(p-chlorophenyl)-1,1-dichloroethylene (DDE), impairs psychomotor development during the first year of life. However, information about the persistence of this association at later ages is limited.We assessed the association of prenatal DDE exposure with child neurodevelopment at 42-60 months of age.Since 2001 we have been monitoring the neurodevelopment in children who were recruited at birth into a perinatal cohort exposed to DDT, in the state of Morelos, Mexico. We report McCarthy Scales of Children's Abilities for 203 children at 42, 48, 54, and 60 months of age. Maternal DDE serum levels were available for at least one trimester of pregnancy. The Home Observation for Measurement of the Environment scale and other covariables of interest were also available.After adjustment, a doubling of DDE during the third trimester of pregnancy was associated with statistically significant reductions of -1.37, -0.88, -0.84, and -0.80 points in the general cognitive index, quantitative, verbal, and memory components respectively. The association between prenatal DDE and the quantitative component was weaker at 42 months than at older ages. No significant statistical interactions with sex or breastfeeding were observed.These findings support the hypothesis that prenatal DDE impairs early child neurodevelopment; the potential for adverse effects on development should be considered when using DDT for malaria control.
Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors.
Authors: P. J. Woll, K. N. Moore, S. Bhatia, F. V. Fossella, L. C. Chen, M. O'Brien, P. Lorigan, S. D. Weitman, J. J. O'Leary, S. Zildjian, E. Bulger, R. Guild, M. H. Shah
Journal: Journal of Clinical Oncology (2011)

e13582 Background: Lorvotuzumab mertansine is a conjugate of the cytotoxic maytansinoid, DM1, and the CD56-binding antibody, lorvotuzumab, and is designed to bind to and kill CD56-expressing cancer cells. Approximately 55-60% of ovarian cancer (OC) and virtually all small-cell lung cancer (SCLC) and Merkel cell carcinoma (MCC) tumors express CD56. After establishing the MTD of lorvotuzumab mertansine in a dose-finding phase, patient enrollment was initiated in an expansion phase to assess the compound in patients with OC, SCLC, or MCC. While assessment in MCC and SCLC has been ongoing, patients with OC only recently began to enter the study. Methods: The expansion phase is open to patients with relapsed or refractory SCLC who have received only one prior therapy and to patients with MCC or OC who have received at least one prior therapy. Patients must meet standard eligibility criteria. However, patients with neurological toxicity ≥ grade 2 or recent history of pancreatitis are excluded. Approximately 100 patients are planned for accrual, with response assessed according to RECIST criteria. In addition, PK and pharmacodynamics correlative studies are being conducted. Lorvotuzumab mertansine is administered intravenously for 3 consecutive days every 21 days at the recommended phase II dose of 60 mg/m2/day. Results: Eighty-five patients have been enrolled in this study with 33 (9-SCLC, 14-MCC, 7-OC, 3-Other) patients treated in the expansion cohort. Objective responses were observed in three patients (1 CR in MCC, 1 clinical CR in MCC, 1 unconfirmed PR in SCLC). Protocol-defined SD was seen in 18 patients with a subset of 15 patients experiencing clinically relevant TTP (≥75 days). Updated efficacy and safety data for all patients will be reported, including the first experience with the compound in OC. Conclusions: Lorvotuzumab mertansine has shown preliminary evidence of meaningful clinical activity with an acceptable safety profile, with experience in OC now being gained.
THE EFFECT OF AMINOPTERIN AND PARTIAL EXSANGUINATION TRANSFUSION ON A CASE OF ACUTE STEM CELL LEUKEMIA; A CASE REPORT AND REVIEW OF THE LITERATURE ON THESE TWO PROCEDURES
Authors: R T ROSS, C B SCHOEMPERLEN
Journal: Annals of Internal Medicine (1950)

ExcerptIt is the purpose of this paper to present the clinical and hematological response of a case of acute stem cell leukemia to aminopterin and to partial exsanguination transfusion.The treatment of leukemia entered a new phase with the advent of the antifolic acid substances. These have been discussed by Farber1 and more recently by Dameshek.5 Also, there have been several reports of the effect of transfusions of whole blood6, 7 and of plasma2, 4 on the natural course of leukemia. Some of the effects of both aminopterin and partial exsanguination transfusion are exhibited in the following case.CASE REPORT
UK child poverty falls by a third
Authors: Zosia Kmietowicz
Journal: BMJ (2001)

The number of children affected by poverty in the United Kingdom has fallen by a third in the past two years, a new report by the Child Poverty Action Group has stated.

Three million children in the United Kingdom continue to live in poverty, however, with a further 2.4 million affected by “multiple deprivation.” This means that despite sacrifices by their parents these children go without two or more necessities, such as …
Histamine nasal provocation test
Authors: P. H. VAN DE HEYNING, J. VAN HAESENDONCK, W. CRETEN, D. DE SAEGHER, J. CLAES
Journal: Allergy (1989)

This study is a methodological approach to histamine nasal provocation. The test uses active anterior rhinomanometry and a histamine titration method, challenging both nasal cavities with a metered dose pump. It has been confirmed that the histamine nasal provocation test can differentiate between controls and non‐allergic rhinitis patients. This study shows, moreover, that the method is more sensitive in assessing response to histamine provocation when a 25% increase of post‐saline nasal airway resistance (PD 25 ) is considered than a PD 50 or PD 100 criterion. The histamine response, was found to be independent of the baseline nasal airway resistance value. Pronounced unilateral responsiveness was frequently noticed. Both nasal cavities should be challenged and the most reactive side considered.
Ipecacuanha in Emetic Doses: As a Stimulant, Restorative, Eliminative, and Adjuvant, in Various Cases of Disorder and Disease
Authors: J. Higginbottom
Journal: BMJ (1869)

Syncope Senilis.-There is a serious complaint which I have denominated syncope senilis, arising from gastric irritation (Lancet, April, 1856).I gave the name of syncope senilis to this affection, to direct the atten-
Abstract 66: Heart-Type Fatty Acid-Binding Protein (H-Fabp) Strongly Correlates with in Hospital Mortality of Pulmonary Artery Embolic Events
Authors: Alessandra Boscheri, Carsten Wunderlich, Joerg Fuhrmann, Alexander Schmeisser, Ruediger Braun-Dullaeus, Ruth H Strasser
Journal: Circulation (2006)

Accumulating evidence indicates that elevated serum troponin levels are a reliable indicator of myocardial injury in patients with acute pulmonary artery embolism (PE) that additionally correlates with in hospital mortality in such individuals. Recent investigations have demonstrated that heart-type fatty acid-binding protein (H-FABP) enables early and precise diagnosis and risk assessment of acute coronary syndrome as compared with other biomarkers. Currently there are no data whether this marker is useful in patients with PE. Therefore the aim of the present study was to determine whether H-FABP may be useful as a prognostic marker for these patients. Consecutive patients (n=39) with confirmed PE were included in the study. Besides serial measurements of cardiac troponin I (cTnI), D- dimer and creatine kinase (CK), a qualitative H-FABP-test (CardioDetect ® med, rennesens, Berlin) was performed on arrival at the intensive care unit and 1 hour afterwards. The positive cut-off for this test was 7ng/ml. Echocardiography was performed in all patients with specific focus on the right ventricular parameters. Of the included 39 patients, 7 had positive H-FABP-tests. Echocardiographic right ventricular function was moderately to severely deteriorated with typical ventricular motion abnormality in all 7 patients of the positive group and in none of the negative group (p
MCF7 breast cancer cells inhibit TNF-alpha production by CD8+ T cells
Authors: Adeeb Al-Zoubi, Rahaf Al-Zoubi, Mohammad El-Khateeb
Journal: Clinical Cancer Research (2008)

A39   Failure of immune surveillance against cancer is a major cause of cancer development. Several studies have shown that breast cancer patients possess specific populations of lymphocytes that are capable of attacking their breast cancer cells. Pro-inflammatory cytokines, such as Tumor Necrosis Factor-Alpha (TNF-a) and Interferon gamma (IFN-g), that are secreted by breast tumor-infiltrating lymphocytes (TILs) play vital roles in the immune response against breast cancer. On the other hand, tumor cells have been shown to develop various immune evasion mechanisms, including the down-regulation of anti-tumor immunity. In this study, we aimed at stimulating, isolating, and analyzing specific immune cells that secrete TNF-alpha in response to MCF7 (a breast cancer cell line). Our results show that, when incubating PBMCs with MCF7 cells in the presence of IL-2, the numbers of TNF-a secreting CD8+ T cells were up to 15 times higher (1.54% TNF-a secreting cells out of all CD45+ cells) than PBMCs controls (0.11 %), as revealed by flow cytometry analyses. Interestingly however, and in contrast with the above results, when IL-2 was not added, the numbers of TNF-a secreting CD8+ T cells were down to 10 times lower (
Abstract 15991: Chronic Asthma Predicts Cardiovascular Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Matthew C Tattersall, Mengye Guo, Claudia E Korcarz, Adam D Gepner, R. Graham Barr, Kathleen M Donohue, Robyn L McClelland, Joseph A Delaney, James H Stein
Journal: Circulation (2014)

Background: Chronic asthma and cardiovascular disease (CVD) share a common inflammatory pathophysiology. We hypothesized that chronic asthma requiring daily controller medications is associated with higher CVD risk. Methods: Presence of chronic asthma and use of controller medications (CM; inhaled corticosteroids, leukotriene inhibitors, oral corticosteroids) were assessed in the MESA at Exam 1. Participants were followed for a mean (standard deviation) 9.1 (2.8) years for development of CVD (coronary death, myocardial infarction, angina, stroke, and CVD death). Multivariable Cox regression models were used to assess associations of chronic asthma and CVD. Results: The 6792 MESA participants were 62.2 (10.2) years old: 47% male, 28% African-American, 22% Hispanic and 2% Chinese. The 156 asthmatics that were on CM were compared with the 511 who were asthmatic but not on CM and the 6125 non-asthmatics. Asthmatics on CM, compared to those not on CM and non-asthmatics, respectively had higher age-adjusted levels of C-reactive protein (1.2 [1.2] vs 0.9 [1.2] vs 0.6 [1.2] mg/L) and fibrinogen (379 [88] vs 356 [80] vs 345 [73] mg/dL) (both p&lt;0.006). Asthmatics on CM had the lowest 10-year unadjusted CVD free survival rate of 84.1%, (95% confidence interval [CI] 78.9-90.3%) compared with asthmatics not on CM 91.1%, [95% CI 88.5-93.8%] and non-asthmatics 90.2%, [95% CI 89.4-91%] (p=0.028). After adjustment for age, sex, race, smoking, total and high-density lipoprotein cholesterol, systolic blood pressure, body-mass index, family history, income, anti-hypertensive and lipid medication use, asthmatics on CM had higher risk of CVD events than non-asthmatics (HR 1.6 [95% 1.01-2.5, p=0.040]). CVD-free survival was similar among asthmatics on or not on CM (p=0.155). Discussion: In this large multi-ethnic cohort, asthmatics on CM had a higher CVD event rate compared to non-asthmatics. Increased CVD risk among asthmatics may be related to increased inflammatory stress.
Abstract 756: First MNK degrading agents block phosphorylation of eIF4E, induce apoptosis, and inhibit cell growth, migration and invasion in triple-negative and HER2-overexpressing breast cancer cell lines
Authors: Senthilmurugan Ramalingam, Lalji Gediya, Puranik Purushottamachar, Andrew Kwegyir-Afful, Vidya priyadarsini Ramamurthy, Hannah Mbatia, Vincent Njar
Journal: Cancer Research (2014)

Abstract Introduction: Retinoic acid metabolism blocking agents are known to exhibit a range of anticarcinogenic properties. This study investigated the anticancer efficacy of novel, potent retinamide retinoic acid metabolism blocking agents (RRs) in triple negative and Her 2 overexpressing breast cancer cells. Recent findings suggest that overexpression of eukaryotic translation initiation factor 4E (eIF4E) in breast cancers critically augments CAP-dependent mRNA translation and synthesis of proteins involved in cell growth, cell proliferation, invasion and apoptosis evasion. The oncogenic potential of eIF4E is strictly dependent on serine 209 phosphorylation by upstream MAPK-interacting kinases (Mnk). Targeting Mnk/eIF4E pathway for blocking Mnk function and eIF4E phosphorylation is therefore a novel approach for treating breast cancers particularly for HER-2-positive and triple negative breast cancers that have no indications for endocrine therapy or effective treatment regimes. Methods: Triple negative and Her 2 overexprssing breast cancer cells were treated with retinamide RAMBAs and Mnk inhibitors and evaluated the effects of RRs on growth inhibition, MAPK/Mnk mediated eIF4E protein translational machinery and downstream biological effects in triple negative and Her 2 overexpressing breast cancer cells Results: We report that the degradation of Mnk by RRs in breast cancer cells blocks eIF4E phosphorylation and subsequently inhibits cell growth, invasion and metastasis in addition to inducing apoptosis. Most importantly the anticancer efficacy of RRs was mediated via degrading Mnk rather than inhibiting its kinase activity like Mnk inhibitors (Cercosporamide and CGP 57380). RRs effect on p-eIF4E downregulation and growth inhibition were also far more potent than the clinically relevant retinoids and Mnk inhibitors, cercosporamide and CGP 57380. Conclusion: Together our findings provide the first preclinical proof-of-concept of novel Mnk degrading agents for Mnk based therapeutic treatment of breast cancers. Citation Format: Senthilmurugan Ramalingam, Lalji Gediya, Puranik Purushottamachar, Andrew Kwegyir-Afful, Vidya priyadarsini Ramamurthy, Hannah Mbatia, Vincent Njar. First MNK degrading agents block phosphorylation of eIF4E, induce apoptosis, and inhibit cell growth, migration and invasion in triple-negative and HER2-overexpressing breast cancer cell lines. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 756. doi:10.1158/1538-7445.AM2014-756